AGIOS PHARMACEUTICALS, INC. (AGIO) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 31 days, typically, give or take 6 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Thu, Jul 30, 2026before open 30 8-K
Q1 FY2026Wed, Apr 29, 2026before open 29 8-K
Q4 FY2025Thu, Feb 12, 2026before open 43 8-K
Q3 FY2025Thu, Oct 30, 2025before open 30 8-K
Q2 FY2025Thu, Jul 31, 2025before open 31 8-K
Q1 FY2025Thu, May 1, 2025before open 31 8-K
Q4 FY2024Thu, Feb 13, 2025before open 44 8-K

What they guided beta

Q3 FY2026 "$907.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026, fully funding commercial launches and pipeline programs; company is targeting non-GAAP profitability in 2028 CAMBRIDGE, Mass. , Nov. 5, 2026 – Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the third quarter ended September 30, 2026." exhibit
Q3 FY2026 "The company expects the associated cost savings of these reductions to be realized in 2027." exhibit
Q2 FY2026 "The addition of cevidoplenib diversifies Agios’ rare hematology portfolio and represents an opportunity to unlock up to $1.0 billion in peak U.S. sales potential in this indication. o Agios expects to advance cevidoplenib into Phase 3 development for ITP in the first half of 2028, following completion of additional chemistry, manufacturing, and controls (CMC) development work." exhibit
Q2 FY2026 "Based on these results, Agios will advance AG-236 into a Phase 2/3 development program in polycythemia vera, with initiation of the Phase 2 portion expected in the second half of 2026." exhibit
Q2 FY2026 "Data from this trial are expected in the second half of 2026." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/AGIO
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/AGIO

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

AGIO earnings date badge

HTML

<a href="https://veritasdata.dev/company/AGIO/"><img src="https://veritasdata.dev/embed/AGIO.svg" alt="AGIO earnings date" width="240" height="56"></a>

Markdown

[![AGIO earnings date](https://veritasdata.dev/embed/AGIO.svg)](https://veritasdata.dev/company/AGIO/)

Script

<script async src="https://veritasdata.dev/embed/AGIO.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/AGIO"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.